Efficacy of the meningococcal vaccine against Neisseria gonorrhoeae: a randomised clinical trial (MenGO) [0.03%]
脑膜炎球菌疫苗对淋病奈瑟菌的预防效果：一项随机临床试验（MenGO）
Caroline Thng,Sharareh Eskandari,Fengyi Jin et al.
Caroline Thng et al.
Neisseria gonorrhoeae (NG) causes significant morbidity globally, and no licensed vaccine currently exists. Observational studies suggest the four-component meningococcal B (4CMenB) vaccine may provide cross-protection against NG. We conduc...
Dual-route H5N1 vaccination induces systemic and mucosal immunity in murine and bovine models [0.03%]
一种双重途径的H5N1疫苗诱导了啮齿目和牛模型中的全身性和粘膜免疫性
Joshua Wiggins,Adthakorn Madapong,Eric A Weaver
Joshua Wiggins
Highly pathogenic H5N1 avian influenza (clade 2.3.4.4b) has spread widely among dairy cattle herds since early 2024, causing major economic losses. This zoonotic event emphasizes the urgent need for H5 vaccines eliciting strong, durable, cr...
Development of in vitro airway epithelial model to assess immune response and safety of mucosal adjuvants [0.03%]
体外气道上皮模型的开发，用于评估黏膜佐剂的免疫反应和安全性
David Acosta,Mohammad Rubel Hoq,Kazuyo Takeda et al.
David Acosta et al.
Mucosal vaccines delivered intranasally or by inhalation, can elicit localized immunity that protects mucosal tissues at the site of infection and may reduce transmission of respiratory viruses, including respiratory syncytial virus (RSV), ...
Structural and genetic signatures of two classes of HCV E2 neutralizing face antibodies from non-human primates immunized with a recombinant E1E2 [0.03%]
用重组E1E2免疫的非人灵长类动物中HCV E2表位特异性中和抗体的结构与遗传特征分析
Yen T K Nguyen,Fang Chen,Erick Giang et al.
Yen T K Nguyen et al.
Hepatitis C continues to be a significant public health problem despite advancements in antiviral therapeutics. To eliminate this disease, an effective vaccine against new infections and re-infections is needed. However, to date only one He...
BPZE1 vaccination induces IL-17+ and IL-22+ CD4+ T cells associated with nasal mucosal secretory IgA responses in humans: effects on virulent Bordetella pertussis colonisation [0.03%]
BPZE1 疫苗通过诱导与人鼻黏膜分泌型免疫球蛋白a应答相关的IL-17+和IL-22+ CD4+ T 细胞来影响致病百日咳博德特氏菌定植
Alison R Hill,Diane F Gbesemete,Tyween Coutinho et al.
Alison R Hill et al.
Pertussis remains a major public health challenge due to the inability of current acellular vaccines to prevent Bordetella pertussis colonisation and transmission. The live-attenuated intranasal vaccine, BPZE1, has shown efficacy in protect...
Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccine [0.03%]
AZD1222疫苗三期临床试验中严重及Delta变异毒株COVID-19的病因研究
Holly Janes,Youyi Fong,Ying Huang et al.
Holly Janes et al.
In the phase 3 AZD1222 COVID-19 vaccine trial, anti-Spike (vaccine-matched and Delta) binding IgG antibody concentration and neutralizing antibody (nAb) titer (vaccine-matched+D614G and Delta), measured four weeks post-dose two (D57), were ...
Rational selection of antigenic targets for Group A Streptococcus vaccine: updates, challenges and opportunities [0.03%]
A群链球菌疫苗抗原靶标的选择：现状、挑战与机遇
Melaku Ashagrie Belete,Istvan Toth,Rachel Stephenson et al.
Melaku Ashagrie Belete et al.
Group A Streptococcus (GAS) remains a major global health challenge, causing over half a million deaths annually. Despite nearly a century of research, no licensed vaccine is currently available, due to antigenic diversity, complex host-pat...
A poorly reactogenic lipid nanoparticle-mRNA vaccine unveils an innate immune pathway for adverse reactions [0.03%]
一种低致反应性的脂质纳米颗粒-mRNA疫苗揭示了不良反应的先天免疫途径
Tomohiro Takano,Keigo Kumagai,Hitoshi Iuchi et al.
Tomohiro Takano et al.
Lipid nanoparticle (LNP)-mRNA vaccines robustly activate immune responses, contributing to their high efficacy and frequent adverse reactions (ARs). Here, we identified an LNP-mRNA formulation with a more favorable balanced immunogenicity-r...
An mRNA vaccine confers enhanced protection against herpes simplex virus through an IFN-I-dependent pathway [0.03%]
通过干扰素I依赖性途径，mRNA疫苗可增强HSV防御力
Wenying Zhao,Lingjin Sun,Peng Wang et al.
Wenying Zhao et al.
Herpes simplex virus (HSV) types 1 and 2 cause widespread oral or genital infections, but no prophylactic or therapeutic HSV vaccine has been approved to date. In this study, we developed three mRNA vaccine candidates expressing key viral g...
The current landscape of therapeutic vaccination approaches for treatment of HPV-dependent malignancies [0.03%]
人乳头状瘤病毒相关恶性肿瘤治疗性疫苗的研发现状及展望
Johanne Audouze-Chaud,Ann-Katrin Schlosser,Angelika B Riemer
Johanne Audouze-Chaud
This review provides an overview of current therapeutic human papillomavirus (HPV) vaccination approaches. We review important criteria for their development, and present vaccines currently being actively followed in clinical trials, for pr...